Cargando…
Drug holiday of high-dose denosumab and recovery from osteoclast inhibition using immunohistochemical investigation of 7 patients with medication-related osteonecrosis of the jaw undergoing segmental mandibulectomy
BACKGROUND/PURPOSE: Denosumab is used to treat bone metastases from malignant tumors. Unlike bisphosphonates, denosumab is not deposited in the bone; thus, withdrawal for a relatively short period would help recovery from osteoclast suppression. This study investigated the relationship between drug...
Autores principales: | Sawada, Shunsuke, Sakamoto, Yuki, Kirihigashi, Mako, Kojima, Yuka |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Association for Dental Sciences of the Republic of China
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10547948/ https://www.ncbi.nlm.nih.gov/pubmed/37799892 http://dx.doi.org/10.1016/j.jds.2023.01.021 |
Ejemplares similares
-
A preliminary clinical study of segmental mandibulectomy on medication-related osteonecrosis of the jaw
por: Otsuru, Mitsunobu, et al.
Publicado: (2022) -
Relationship between Drug Holidays of Antiresorptive Agents and Surgical Outcomes in Cancer Patients with Medication-Related Osteonecrosis of the Jaw
por: Otsuru, Mitsunobu, et al.
Publicado: (2022) -
Medication-related osteonecrosis of the jaw without osteolysis on computed tomography: a retrospective and observational study
por: Sakamoto, Yuki, et al.
Publicado: (2023) -
Denosumab and osteonecrosis of the jaw
por: Bower, Robert
Publicado: (2019) -
Osteonecrosis of the jaw and denosumab
por: Goss, Alastair N
Publicado: (2022)